In a murine model, sequential acquisition of ASXL1 and SRSF2 mutations recapitulated features of clonal hematopoiesis and induced progression to MDS/AML, highlighting the biological basis for the adverse clinical outcomes associated with these mutations [82]. The gene discussed is SRSF2; the disease is acute myeloid leukemia.